Literature DB >> 29530485

Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers.

Julian A Gingold1, Dandan Zhu2, Dung-Fang Lee2, Ahmed Kaseb3, Jian Chen4.   

Abstract

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), the two most common primary liver cancers, represent the second most common cancer-related cause of death worldwide, with most cases being diagnosed at an advanced stage. Recent genome-wide studies have helped to elucidate the molecular pathogenesis and genetic heterogeneity of liver cancers. This review of the genetic landscape of HCC and iCCA discusses the most recent findings from genomic profiling and the current understanding of the pathways involved in the initiation and progression of liver cancer. We highlight recent insights gained from metabolic profiling of HCC and iCCA. This knowledge will be key to developing clinically useful diagnostic/prognostic profiles, building targeted molecular and immunologic therapies, and ultimately curing these complex and heterogeneous diseases. Published by Elsevier Ltd.

Entities:  

Keywords:  cholangiocarcinoma; genomic profiling; hepatocellular carcinoma; metabolic reprogramming; obesity-associated microbiota

Mesh:

Year:  2018        PMID: 29530485     DOI: 10.1016/j.molmed.2018.02.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  16 in total

1.  Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma.

Authors:  Jingyu Chen; Anketse Debebe; Ni Zeng; Janel Kopp; Lina He; Maike Sander; Bangyan L Stiles
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

2.  Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.

Authors:  Zeribe C Nwosu; Nadia Battello; Melanie Rothley; Weronika Piorońska; Barbara Sitek; Matthias P Ebert; Ute Hofmann; Jonathan Sleeman; Stefan Wölfl; Christoph Meyer; Dominik A Megger; Steven Dooley
Journal:  J Exp Clin Cancer Res       Date:  2018-09-03

Review 3.  Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.

Authors:  Qi Zhang; Yu Lou; Xue-Li Bai; Ting-Bo Liang
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

Review 4.  Contextual Regulation of TGF-β Signaling in Liver Cancer.

Authors:  Shuo Tu; Wei Huang; Chunhong Huang; Zhijun Luo; Xiaohua Yan
Journal:  Cells       Date:  2019-10-11       Impact factor: 6.600

5.  Identification and Validation of Key Genes in Hepatocellular Carcinoma by Bioinformatics Analysis.

Authors:  Jia Wang; Rui Peng; Zheng Zhang; Yixi Zhang; Yuke Dai; Yan Sun
Journal:  Biomed Res Int       Date:  2021-02-23       Impact factor: 3.411

6.  Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.

Authors:  Yuan Deng; Ming Li; Minghui Zhuo; Peng Guo; Qiang Chen; Pingli Mo; Wengang Li; Chundong Yu
Journal:  J Biol Chem       Date:  2020-12-03       Impact factor: 5.157

7.  ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway.

Authors:  Qifan Zhang; Yunbin Zhang; Shibo Sun; Kai Wang; Jianping Qian; Zhonglin Cui; Tao Tao; Jie Zhou
Journal:  Cell Death Dis       Date:  2021-01-04       Impact factor: 8.469

Review 8.  Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.

Authors:  Hayato Nakagawa; Yuki Hayata; Satoshi Kawamura; Tomoharu Yamada; Naoto Fujiwara; Kazuhiko Koike
Journal:  Cancers (Basel)       Date:  2018-11-15       Impact factor: 6.639

Review 9.  Role of the autophagy-related marker LC3 expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Yu-Chen Meng; Xiao-Li Lou; Li-Yuan Yang; Dong Li; Yan-Qiang Hou
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-10       Impact factor: 4.553

10.  α-enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis.

Authors:  Lihong Zhang; Tao Lu; Ye Yang; Liangfeng Hu
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.